Dr. Reddy's launches new finished dosage plant in India

By Emilie Reymond

- Last updated on GMT

Related tags Dr reddy Dr. reddy Generic drug

Dr. Reddy's Laboratories has announced the inauguration of its
seventh finished dosage plant in India, reflecting the country's
unprecedented growth as a generic pharmaceuticals manufacturer.

Situated in the city of Vishakhapatnam, the new facility is designed to manufacture a broad range of products, including cytotoxic and anti-hormonal products as well as injectibles, catering to the international market for the treatment of cancer, hormonal imbalances and other diseases.

India has already a dominant role in global generic production, accounting for 22 per cent of the global generics market, and according to a recent KPMG report, the Indian pharma industry - currently worth $6bn (€4.7bn) - is growing at ten per cent compared to the global industry rate of seven per cent.

Dr Reddy's said it new unit has been designed to handle potent compounds using isolation technology, with equipment like a fully automated injectible filling line, single pot processors and wash-in-place tablet presses.

The firm also said the new facility represents a significant advance in technical sophistication over its other formulations technical operations (FTO) facilities, of which three are located in Hyderabad, one in Yanam near Kakinada and one in Baddi, Himachal Pradesh.

"With the setting up of this new unit, our key focus is to use the most advanced techniques and our large pool of scientific talent, coupled with superior process R&D skills for rapid process development,"​ said Ashwani Kumar Malhotra, executive vice president of FTO at Dr Reddy's.

"This facility, fully equipped with state-of-the-art infrastructure, will give us a competitive edge."

The plant also has an in-built capacity-expansion capability, keeping in mind the company's product pipeline and global market trends.

Dr. Reddy's Laboratories, established in 1984, is an emerging global pharmaceutical company with proven research capabilities.

The company produces generic finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with a focus on India, USA, Europe and Russia.

It employs over 6,500 people globally with headquarters in Hyderabad, India.

Related topics Markets & Regulations

Related news

Show more